-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$58.50138.68% Upside
Beam Therapeutics Inc. Frequently Asked Questions
-
What analysts cover Beam Therapeutics Inc.?
Beam Therapeutics Inc. has been rated by research analysts at Leerink Partners, BMO Capital, Stifel Nicolaus, Cantor Fitzgerald, Citigroup, Credit Suisse in the past 90 days.